Journament

Keyword Connections - major depressive disorder Keywords

Connection Type	Connection
Journals	progress in neuro-psychopharmacology & biological psychiatry Frontiers in psychiatry Behavioural brain research planta medica Journal of affective disorders Life (Basel, Switzerland) zhonghua yi xue za zhi Journal of nanoscience and nanotechnology Neuropsychiatric disease and treatment Appetite neuroimage clinical clinical neurophysiology : official journal of the international federation of clinical neurophysiology BMC psychiatry pharmacology, biochemistry, and behavior Nursing for women's health australian and new zealand journal of public health brain research bulletin bone marrow transplantation brain stimulation the world journal of biological psychiatry : the official journal of the world federation of societies of biological psychiatry alternative medicine review : a journal of clinical therapeutic
Research Groups	No Research Group Connected
Bibliographies	[1] Natural health products, dietary minerals and over-the-counter medications as add-on therapies to antidepressants in the treatment of major depressive disorder: a review. [2] The Efficacy of Saffron in the Treatment of Mild to Moderate Depression: A Meta-analysis. [3] Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: a randomized, double-blind, placebo-controlled, pilot clinical trial. [4] Using text mining to extract depressive symptoms and to validate the diagnosis of major depressive disorder from electronic health records. [5] Altered dynamic functional connectivity in weakly-connected state in major depressive disorder. [6] High prevalence of CD3, NK, and NKT cells in the graft predicts adverse outcome after matched-related and unrelated transplantations with post transplantation cyclophosphamide. [7] C-reactive protein: A differential biomarker for major depressive disorder and bipolar II disorder. [8] Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural-functional synergies with cell membrane phospholipids. [9] Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study. [10] Anhedonic-like behavior correlates with IFNγ serum levels in a two-hit model of depression. [11] Overeating and food addiction in Major Depressive Disorder: Links to peripheral dopamine. [12] A cluster randomized controlled trial of an online psychoeducational intervention for people with a family history of depression. [13] [A pilot study of transcranial alternating current stimulation in the treatment of drug-naive adult patients with major depressive disorder]. [14] Decreased plasma glial cell line-derived neurotrophic factor level in major depressive disorder is associated with age and clinical severity. [15] Impact of Cognitive Symptoms on Health-Related Quality of Life and Work Productivity in Chinese Patients with Major Depressive Disorder: Results from the PROACT Study. [16] Harmful drinking is associated with mental health conditions and other risk behaviours in Australian young people. [17] Subtypes of Depression: Latent Class Analysis in Spanish Old People with Depressive Symptoms. [18] neuroinflammation and behaviour [19] brain-derived neurotrophic factor and major depressive disorder: evidence from meta-analyses [20] depressive-like behavioural profiles in captive-bred single- and socially-housed rhesus and cynomolgus macaques: a species comparison [21] symptom severity, affective and somatic symptom clusters predict poorer social cognition performance in current but not remitted major depressive disorder [22] t cell phenotype and t cell receptor repertoire in patients with major depressive disorder [23] subjective mood in young unmedicated depressed women under high and low sleep pressure conditions [24] determining the role of gender in relation between sexual desire and quality of life in patients with major depression [25] a review of the role of social cognition in major depressive disorder [26] changes of grey matter volume in first-episode drug-naive adult major depressive disorder patients with different age-onset [27] exercise leads to better clinical outcomes in those receiving medication plus cognitive behavioral therapy for major depressive disorder [28] neural activity during interoceptive awareness and its associations with alexithymia – an fmri study in major depressive disorder and non-psychiatric controls [29] pattern separation: a potential marker of impaired hippocampal adult neurogenesis in major depressive disorder [30] Prediction of Probable Major Depressive Disorder in the Taiwan Biobank: An Integrated Machine Learning and Genome-Wide Analysis Approach [31] Plasma alpha-trypsin inhibitor heavy chain 4 as an age-specific biomarker in the diagnosis and treatment of major depressive disorder. [32] Relationship of cognitive impairment with depressive symptoms and psychosocial function in patients with major depressive disorder: Cross-sectional analysis of baseline data from PERFORM-J. [33] Sex-specific plasma metabolome signatures in major depressive disorder. [34] The paradox of relaxation training: Relaxation induced anxiety and mediation effects of negative contrast sensitivity in generalized anxiety disorder and major depressive disorder. [35] Association of thyroid dysfunction with suicide attempts in first-episode and drug naïve patients with major depressive disorder. [36] Ratio of plasma BDNF to leptin levels are associated with treatment response in major depressive disorder but not in panic disorder: A 12-week follow-up study. [37] An Online Mindfulness-Based Cognitive Behavioral Therapy Intervention for Youth Diagnosed With Major Depressive Disorders: Protocol for a Randomized Controlled Trial. [38] White matter disturbances in major depressive disorder: a coordinated analysis across 20 international cohorts in the ENIGMA MDD working group. [39] Comorbidity with more anxiety disorders associated with a poorer prognosis persisting at the 10-year follow-up among patients with major depressive disorder. [40] Major depressive disorder in children and adolescents. [41] Abnormal functional connectivity strength in first-episode, drug-naïve adult patients with major depressive disorder. [42] Investigating executive control network and default mode network dysfunction in major depressive disorder. [43] Blame-rebalance fMRI neurofeedback in major depressive disorder: A randomised proof-of-concept trial. [44] Natural health products, dietary minerals and over-the-counter medications as add-on therapies to antidepressants in the treatment of major depressive disorder: a review. [45] Comparative efficacy and safety of L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials. [46] Crocus sativus L. versus Citalopram in the Treatment of Major Depressive Disorder with Anxious Distress: A Double-Blind, Controlled Clinical Trial. [47] Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: a randomized, double-blind, placebo-controlled, pilot clinical trial. [48] Comparative efficacy and safety of Crocus sativus L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials [49] Using text mining to extract depressive symptoms and to validate the diagnosis of major depressive disorder from electronic health records. [50] Altered dynamic functional connectivity in weakly-connected state in major depressive disorder. [51] Indices of insulin resistance and glucotoxicity are not associated with bipolar disorder or major depressive disorder, but are differently associated with inflammatory, oxidative and nitrosative biomarkers. [52] C-reactive protein: A differential biomarker for major depressive disorder and bipolar II disorder. [53] Amygdala astrocyte reduction in subjects with major depressive disorder but not bipolar disorder [54] Cognition in older adults with bipolar disorder versus major depressive disorder [55] Novel markers of inflammation and their relevance to depression: The unique relation of the Neutrophil: Lymphocyte Ratio (NLR) and the Cortisol:C-reactive protein (CORT/CRP) ratio to an intermediate phenotype of Major Depressive Disorders (MDD) [56] An overview of the heterogeneity of major depressive disorder: Current knowledge and Future prospective. [57] The Cost-Effectiveness of Cognitive Behavioral Therapy Versus Second-Generation Antidepressants for Initial Treatment of Major Depressive Disorder in the United States: A Decision Analytic Model. [58] The Relationship Between Smoking and Suicidal Behavior in Psychiatric Patients with Major Depressive Disorder [59] Adverse childhood experiences and alexithymia in patients with major depressive disorder. [60] Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. [61] Quantifying the level of difficulty to treat major depressive disorder with antidepressants: Treatment Resistance to Antidepressants Evaluation Scale. [62] Overeating and food addiction in Major Depressive Disorder: Links to peripheral dopamine. [63] [A pilot study of transcranial alternating current stimulation in the treatment of drug-naive adult patients with major depressive disorder]. [64] Sex differences on the relation between major depressive disorder and labor market outcomes: A national prospective study. [65] Decreased plasma glial cell line-derived neurotrophic factor level in major depressive disorder is associated with age and clinical severity. [66] Impact of Cognitive Symptoms on Health-Related Quality of Life and Work Productivity in Chinese Patients with Major Depressive Disorder: Results from the PROACT Study. [67] Major Depressive Disorder Is Associated With Cardiovascular Risk Factors and Low Omega-3 Index [68] Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive Disorder [69] Review of Maintenance Trials for Major Depressive Disorder: A 25-Year Perspective From the US Food and Drug Administration [70] Major Depressive Disorder Predicts Completion, Adherence, and Outcomes in Cardiac Rehabilitation: A Prospective Cohort Study of 195 Patients With Coronary Artery Disease [71] Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity [72] Failure Rate and “Professional Subjects” in Clinical Trials of Major Depressive Disorder [73] Reply to Failure Rate and “Professional Subjects” in Clinical Trials of Major Depressive Disorder [74] Report by the ACNP Task Force on response and remission in major depressive disorder [75] Procognitive Effects of Antidepressants and Other Therapeutic Agents in Major Depressive Disorder: A Systematic Review [76] Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder [77] Duloxetine, 60 mg Once Daily, for Major Depressive Disorder: A Randomized Double-Blind Placebo-Controlled Trial [78] genome-wide analysis in uk biobank identifies four loci associated with mood instability and genetic correlation with major depressive disorder, anxiety disorder and schizophrenia [79] brain-derived neurotrophic factor and major depressive disorder: evidence from meta-analyses [80] cost-effectiveness of collaborative care including pst and an antidepressant treatment algorithm for the treatment of major depressive disorder in primary care; a randomised clinical trial [81] symptom severity, affective and somatic symptom clusters predict poorer social cognition performance in current but not remitted major depressive disorder [82] t cell phenotype and t cell receptor repertoire in patients with major depressive disorder [83] p300 latency as an indicator of severity in major depressive disorder [84] does duloxetine improve cognitive function independently of its antidepressant effect in patients with major depressive disorder and subjective reports of cognitive dysfunction? [85] a review of the role of social cognition in major depressive disorder [86] major depressive disorder with melancholia displays robust alterations in resting state heart rate and its variability: implications for future morbidity and mortality [87] analysis of the association of mir124-1 and its target gene rgs4 polymorphisms with major depressive disorder and antidepressant response [88] changes of grey matter volume in first-episode drug-naive adult major depressive disorder patients with different age-onset [89] exercise leads to better clinical outcomes in those receiving medication plus cognitive behavioral therapy for major depressive disorder [90] c-quality: cost and quality-of-life pharmacoeconomic analysis of antidepressants used in major depressive disorder in the regional italian settings of veneto and sardinia [91] neural activity during interoceptive awareness and its associations with alexithymia – an fmri study in major depressive disorder and non-psychiatric controls [92] pattern separation: a potential marker of impaired hippocampal adult neurogenesis in major depressive disorder [93] formulating a return-to-work decision for employees with major depressive disorders: occupational therapists’ experiences [94] desvenlafaxine in the treatment of major depressive disorder [95] depression reduces accuracy while parkinsonism slows response time for processing positive feedback in patients with parkinson’s disease with comorbid major depressive disorder tested on a probabilistic category-learning task [96] preventive effect of liothyronine on electroconvulsive therapy-induced memory deficit in patients with major depressive disorder: a double-blind controlled clinical trial [97] effect of an educational booklet on knowledge and attitude regarding major depressive disorder in medical students in delhi [98] abnormal white matter integrity in chinese young adults with first-episode medication-free anxious depression: a possible neurological biomarker of subtype major depressive disorder [99] reduced fractional anisotropy in patients with major depressive disorder and associations with vascular stiffness [100] Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset [101] Duloxetine Efficacy for Major Depressive Disorder in Male vs. Female Patients: Data From 7 Randomized, Double-Blind, Placebo-Controlled Trials